Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;37(4):216-227.
doi: 10.5021/ad.24.154.

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors

Hyun-Chang Ko #  1 , Yu Ri Woo #  2 , Joo Yeon Ko  3 , Hye One Kim  4 , Chan Ho Na  5 , Youin Bae  6 , Young-Joon Seo  7 , Min Kyung Shin  8 , Jiyoung Ahn  9 , Bark-Lynn Lew  8 , Dong Hun Lee  10 , Sang Eun Lee  11 , Sul Hee Lee  12 , Yang Won Lee  13 , Ji Hyun Lee  14 , Yong Hyun Jang  15 , Jiehyun Jeon  16 , Sun Young Choi  17 , Ju Hee Han  14 , Tae Young Han  18 , Sang Wook Son  19 , Sang Hyun Cho  20
Affiliations

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors

Hyun-Chang Ko et al. Ann Dermatol. 2025 Aug.

Abstract

Background: Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed.

Objective: This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based recommendations.

Methods: The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved.

Results: This guideline provides treatment guidance on advanced systemic treatment modalities for AD. In particular, the guideline offers up-to-date treatment recommendations for biologics and Janus-kinase inhibitors used in the treatment of patients with moderate to severe AD. It also provides guidance on other therapies for AD, along with tailored recommendations for children, adolescents, the elderly, and pregnant or breastfeeding women.

Conclusion: KADA's updated AD treatment guidelines incorporate the latest evidence and expert opinion to provide a comprehensive approach to AD treatment. The guidelines will help clinicians optimize patient-specific therapies.

Keywords: Atopic dermatitis; Biologics; Consensus; Guideline; Janus Kinase inhibitors; Republic of Korea.

PubMed Disclaimer

Conflict of interest statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Figures

Fig. 1
Fig. 1. Treatment algorithm for patients with atopic dermatitis in Korea. The text in bold indicates a treatment with recommendation A (strong recommendation for using an intervention).
AD: atopic dermatitis, JAK: Janus-kinase. *Switchable in insufficient response† or intolerable due to adverse effects. †Insufficient response is defined as an AD patient who fails to achieve Eczema Area and Severity Index 50, or meets one or more of the following criteria after 3 months of appropriate treatment: a daytime or nighttime itch numeric rating scale score ≥4, or a Dermatology Life Quality Index ≥6.
See this image and copyright information in PMC

References

    1. Kim JE, Shin MK, Park GH, Lee UH, Lee JH, Han TY, et al. 2019 Consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: objective and subjective assessment of severity. Ann Dermatol. 2019;31:654–661. - PMC - PubMed
    1. Lee JH, Kim JE, Park GH, Bae JM, Byun JY, Shin MK, et al. Consensus update for systemic treatment of atopic dermatitis. Ann Dermatol. 2021;33:497–514. - PMC - PubMed
    1. Ahn J, Choi Y, Simpson EL. Therapeutic new era for atopic dermatitis: part 1. biologics. Ann Dermatol. 2021;33:1–10. - PMC - PubMed
    1. Lee SJ, Kim SE, Shin KO, Park K, Lee SE. Dupilumab therapy improves stratum corneum hydration and skin dysbiosis in patients with atopic dermatitis. Allergy Asthma Immunol Res. 2021;13:762–775. - PMC - PubMed
    1. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) Br J Dermatol. 2018;178:1083–1101. - PubMed

LinkOut - more resources